Immune checkpoint inhibitors (ICIs), which block PD-1 and PD-L1 interaction, play a role in the reversal of T cell exhaustion and clinical data suggests that patients whose tumor overexpress PD-L1 exhibit better clinical response to immune checkpoint therapy [44]. This evidence concerns the gene CD274 and neoplasm.